共 124 条
[1]
Jemal A(2008)Cancer statistics, 2008 CA Cancer J Clin 58 71-96
[2]
Siegel R(1997)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403-2413
[3]
Ward E(2007)Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 1960-1966
[4]
Hao Y(1992)Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro J Natl Cancer Inst 84 1238-1244
[5]
Xu J(2005)Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines Int J Gastrointest Cancer 36 15-28
[6]
Murray T(2009)Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells Invest New Drugs 27 89-98
[7]
Thun MJ(2000)Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon Biochem Pharmacol 60 749-758
[8]
Burris HA(2006)Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice Anticancer Drugs 17 1179-1184
[9]
Moore MJ(2007)Phase I trial of imexon in patients with advanced malignancy J Clin Oncol 25 1779-1784
[10]
Andersen J(1997)Preclinical, pharmacologic, and phase I studies of gemcitabine Semin Oncol 24 S7-2-S7-7